人类乳突病毒(HPV)检验的全球市场，市场规模和占有率的分析 - 成长趋势与预测(2025年～2033年)

人类乳突病毒 (HPV) 检测市场趋势及总结

2024 年全球人类乳突病毒 (HPV) 检测市场规模为 15.2 亿美元，预计到 2033 年将达到 36.2 亿美元，2025 年至 2033 年的复合年增长率为 10.11%。这一增长得益于人们对子宫颈癌认识的不断提高、筛检计画的不断推进以及全球医疗保健系统诊断技术的进步。

人类乳突病毒 (HPV) 检测市场成长动力

提高意识和政府筛检计画

国际宣传项目和国家筛检计画显着增加了 HPV 检测的需求。已开发经济体和新兴经济体的政府都已推出指南，要求30岁及以上女性定期进行子宫颈癌筛检。世界卫生组织（WHO）等组织倡导HPV检测作为早期发现癌症的关键工具。人们对HPV相关癌症的认识不断提高以及疫苗接种也推动了这项需求。这些措施将有助于更早诊断、更快介入，并减轻HPV相关疾病的整体负担，从而推动市场向前发展。 2024年9月，美国、澳洲、印度和日本将​​在印度-太平洋地区大力展开对抗子宫颈癌的行动。这些行动是四方领导人峰会上宣布的一项重大举措的一部分。

HPV检测的技术突破

PCR、新一代定序和自采集试剂盒等诊断技术的创新，透过提高准确性、可及性和便利性，彻底改变了HPV检测。自动化平台、多重检测和液基细胞学技术可以缩短检测週期并实现大规模筛检。这些技术在资源匮乏的环境中尤其有价值，使其能够在公共卫生系统中得到更广泛的应用。诊断公司持续的研发投入有助于提高检测的灵敏度和可用性，从而进一步推动市场成长。 2023年6月，世界卫生组织初步核准了第四种人类乳突病毒 (HPV) 检测方法。 HPV 检测对于子宫颈癌筛检至关重要，因为大多数 HPV 感染会自然消退，但多种高风险 HPV 类型都可能导致子宫颈癌。

HPV 相关癌症盛行率上升

全球 HPV 相关癌症（尤其是子宫颈癌）发生率的上升是强大的市场驱动力。据世界卫生组织称，子宫颈癌是全球第四大常见女性癌症，其中绝大多数是由高危险 HPV 类型引起的。癌症患者数量的增加增加了对早期检测策略的需求，使 HPV 检测成为预防医学的核心。随着医疗保健专业人员和患者寻求可靠的诊断方法，HPV 检测也正成为女性医疗保健的重要组成部分。在美国，每年约有47,984例新发癌症病例发生在人类乳突病毒 (HPV) 常见的身体部位。

人类乳突病毒 (HPV) 检测市场面临的课题

低收入国家/地区的可近性受限

儘管 HPV 检测在全球范围内得到认可，但由于缺乏医疗保健基础设施和资源，在中低收入国家/地区并不容易获得。大多数地区缺乏检测设施、训练有素的专业人员和定期筛检项目。文化禁忌和性歧视也阻碍了人们参与 HPV 检测。这种差异导致人们无法获得早期诊断，并增加了晚期子宫颈癌的风险。透过经济高效的即时诊断和教育计划克服这些障碍，对于公平的市场扩张至关重要。

先进HPV侦测技术成本高

先进的HPV检测技术（包括基于PCR的平台和DNA定序）的价格可能超出医疗保健系统和某些患者的承受能力。由于已开发国家已将这些技术用于常规筛检，因此价格差异限制了其在资源匮乏地区的应用。此外，维护成本、品质保证以及对专业人员的需求导致诊所和实验室的运作成本高昂。这项成本因素阻碍了大规模筛检活动的发展，尤其是在发展中国家。

本报告提供全球人类乳突病毒(HPV)检验市场相关调查，成长推动因素与课题，各市场区隔的分析，主要企业的分析等资讯。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场动态

• 成长促进因素
• 课题

第5章 人类乳突病毒(HPV)检验市场

• 过去的市场趋势
• 市场预测

第6章 人类乳突病毒(HPV)检验的市场占有率分析

• 各用途
• 各产品
• 各技术
• 各最终用途
• 各国

第7章 用途

• 子宫颈癌症诊察
• 阴道癌症诊察

第8章 产品

• 消耗品
• 器具
• 服务

第9章 技术

• 聚合酵素链锁反应(PCR)
• 液状化检体细胞诊断
• 免疫诊断
• 杂交捕获
• 其他

第10章 最终用途

• 医院·诊疗所
• 研究所
• 其他

第11章 国家

• 北美
  • 美国
  • 加拿大
• 欧洲
  • 法国
  • 德国
  • 义大利
  • 西班牙
  • 英国
  • 比利时
  • 荷兰
  • 土耳其
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 泰国
  • 马来西亚
  • 印尼
  • 澳洲
  • 纽西兰
• 南美
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东·非洲
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非

第12章 波特的五力分析

第13章 SWOT分析

第14章 主要企业的分析

• Abbott Laboratories
• BioMerieux SA
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• Siemens Healthineers AG
• Hologic Inc
• Qiagen NV
• F. Hoffmann-La Roche Ltd

Human Papilloma Virus (HPV) Testing Market Trends & Summary

The Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnostic technologies in global healthcare systems.

The report Human Papilloma Virus (HPV) Testing Market & Forecast covers by Application (Cervical Cancer Screening, Vaginal Cancer Screening), Product (Consumables, Instruments, Services), Technology (Polymerase chain reaction (PCR), Liquid-based cytology, Immunodiagnostics, Hybrid Capture, Others), End Use (Hospitals & Clinics, Laboratories, Others), Countries and Company analysis 2025-2033.

Human Papilloma Virus (HPV) Testing Market Outlooks

Human Papilloma Virus (HPV) testing is a clinical diagnostic test conducted to identify the existence of HPV DNA or RNA in cells, mostly from the cervix. HPV is an epidemic sexually transmitted infection and some high-risk types are recognized to be causative for cervical cancer, as well as other anogenital and oropharyngeal cancers. HPV testing is generally done in regular cervical cancer screenings, typically at the same time or after a Pap test. It allows identifying women who are at risk prior to cell abnormality occurrence so that it may be prevented or treated early.

Internationally, the use of HPV testing is increasing with growing awareness regarding prevention of cervical cancer, government-sponsored screening programs, and WHO's initiative to eliminate cervical cancer as a public health issue. Developed countries have embraced HPV-based screening on a large scale, and developing nations are also adopting it, with the support of global health programs. Its high sensitivity and long-term risk prediction make it a method of choice in contemporary gynecological practice.

Growth Driver in the Human Papilloma Virus (HPV) Testing Market

Increasing Awareness and Government Screening Programs

International awareness programs and country-level screening programs have increased demand for HPV testing to a large extent. Governments in developed and emerging economies are adopting routine cervical cancer screening guidelines for women aged 30 and older. WHO organizations advocate for HPV testing as a key tool for early detection of cancer. Greater awareness of HPV-associated cancers and immunization also reinforces demand. These efforts account for early diagnosis, prompt intervention, and overall reduction in HPV-associated disease burden, thus driving the market forward. SEP 2024, The United States, Australia, India, and Japan are rolling out a key initiative to fight cervical cancer across the Indo-Pacific, a preventable disease which is a significant health crisis in the region. This initiative is part of larger announcements made during the Quad Leaders Summit.

Technological Breakthroughs in HPV Testing

Innovation in diagnostic methods-like PCR, next-generation sequencing, and self-sampling kits-has revolutionized HPV testing by enhancing accuracy, accessibility, and convenience. Automated platforms, multiplex assays, and liquid-based cytology enable quicker turnaround times and large-scale screening. These technologies are particularly precious in resource-poor settings and enable wider adoption in public health systems. Ongoing R&D spending by diagnostic firms serves to improve test sensitivity and affordability, fueling additional market growth. June 2023, The WHO has prequalified a fourth test for human papillomavirus (HPV). Although most HPV infections will clear on their own, a few of the higher-risk types can cause cervical cancer, so HPV testing is important for cervical cancer screening.

Rising Prevalence of HPV-Associated Cancers

Growing global incidence of HPV-related cancers, particularly cervical cancer, is a strong market driver. Cervical cancer is the fourth leading female cancer in the world according to the WHO, and the overwhelming majority of cases are caused by high-risk HPV types. Growing cases of cancer have driven the need for early detection strategies, putting HPV testing at the center of preventive medicine. As healthcare professionals and patients strive for surefire diagnostic measures, HPV testing is also becoming a necessity in women's health care. An estimated 47,984 new cases of cancer occur each year in the United States in areas of the body where human papillomavirus (HPV) commonly occurs.

Challenge in the Human Papilloma Virus (HPV) Testing Market

Limited Access in Low-Income Countries

In spite of worldwide awareness, HPV testing is not readily available in low- and middle-income countries because of a lack of healthcare infrastructure and resources. There are few laboratory facilities, skilled professionals, and regular screening programs in most areas. Cultural taboo and sexual stigma also discourage HPV testing participation. This inequality avoids early diagnosis and enhances the risk of cervical cancer at advanced stages. It is essential to overcome these barriers using cost-effective point-of-care diagnostics and education initiatives for equitable market expansion.

Exorbitant Cost of Sophisticated HPV Testing Technologies

The price of advanced HPV testing technologies, including PCR-based platforms and DNA sequencing, can be out of reach for healthcare systems and some patients. As developed nations implement these technologies into regular screening, the affordability gap restricts accessibility in resource-scarce settings. In addition, maintenance costs, quality assurance, and specialized staff requirements contribute to higher operating costs for clinics and laboratories. This cost factor hinders mass screening activities, particularly in developing countries.

Human Papilloma Virus Cervical Cancer Testing Market

Cervical cancer testing is the leading segment in the HPV testing market. Almost all cervical cancers are associated with persistent infection with high-risk HPV types, so early detection is essential. Governments and NGOs are encouraging HPV-based cervical cancer screening to supplement or replace conventional Pap smears. Incorporation of HPV DNA testing in primary screening algorithms enhances detection rates and long-term surveillance. This trend has raised the demand for dependable, sensitive, and scalable testing solutions, considerably boosting the cervical cancer testing market.

Consumables Human Papilloma Virus Testing Market

Consumables such as reagents, assay kits, swabs, and sample collection devices make up a crucial part of the HPV testing market. With reoccurring testing and increasing use of self-sampling kits, the need for superior consumables is increasing consistently. Diagnostic clinics and laboratories depend on regular supply and compatibility with multiple automated platforms. Additionally, innovation in multiplex testing and sample preservation has resulted in the creation of sophisticated consumables, providing improved stability and accuracy. This consumables segment provides recurring revenue, supporting market growth.

Immunodiagnostics Human Papilloma Virus Testing Market

Immunodiagnostics HPV tests identify particular viral proteins or host immune reactions through antibody-antigen interactions. These assays are simpler than molecular methods and are commonly employed in screening programs, especially in resource-constrained environments. They represent a cost-saving alternative for identifying high-risk HPV types and early cervical lesions. While less sensitive than PCR, continued advances in immunoassay design and the discovery of biomarkers are improving reliability. This section is important in making HPV testing available in various healthcare settings.

Polymerase Chain Reaction (PCR) Human Papilloma Virus Testing Market

PCR-based HPV tests are considered the gold standard for high-risk HPV detection based on their enhanced sensitivity and specificity. Multiple HPV genotypes can be identified with these tests in a single assay, which facilitates accurate risk stratification and monitoring. Increasing clinical use of real-time PCR and multiplex platforms has driven the market strongly. Automation and cost-saving measures are rendering PCR testing more viable in large-scale screening programs. With precision diagnostics becoming more prominent, PCR continues to be a mainstay in HPV testing.

Human Papilloma Virus Testing Laboratories Market

Test-based HPV laboratory testing leads the market with high-volume, high-precision, scalable offerings of centralized laboratories. The laboratories provide standardized test protocols to hospitals, public health programs, and private clinics. Diagnostic laboratories are embracing automation, high-capacity platforms, and LIMS integration as demand for cervical cancer screening increases. Reference laboratories and outsourcing services have led to strong, long-term growth for this market segment.

United States Human Papilloma Virus Testing Market

The U.S. market for HPV testing is developed and ongoing because of extensive awareness, national screening initiatives, and high usage of sophisticated diagnostics. Routine screening for HPV in women is advised by the CDC, and the services are usually covered by insurers. Technological advancements, robust regulatory backing, and dominance of major players make the U.S. a focal point for HPV diagnostics. Demand for home and self-collection kits is also increasing, thus fueling diversification in the market.

France Human Papilloma Virus Testing Market

In France, the HPV testing market is growing steadily with the integration of HPV screening into the national health system. Since 2020, HPV testing has been recommended as the primary screening method for women aged 30 and above, replacing the Pap smear. The French government subsidizes screening, raising participation and test volumes. With a solid public health infrastructure and improving awareness, the market is moving toward automated molecular testing platforms and large-scale laboratory operations.

India Human Papilloma Virus Testing Market

India's HPV testing market is in the growth stage, fueled by rising awareness and pilot screening across different states. Adoption is restricted to urban areas and private healthcare due to cost and infrastructure reasons. Government and NGOs are enforcing broader accessibility through low-cost testing solutions and mobile health vans. With a heavy load of cervical cancer, India has huge long-term potential, particularly as domestic manufacturers and public policy reduce costs.

Saudi Arabia Human Papilloma Virus Testing Market

The Saudi Arabian market for HPV testing is growing as the government continues to focus more on women's health and prevention of cancer. The Ministry of Health is initiating HPV vaccination and screening programs, particularly in private clinics and urban hospitals. Despite initial resistance from cultural sensitivity, awareness campaigns and education are slowly enhancing test acceptance. With a young, technologically savvy population and continued healthcare reform under Vision 2030, Saudi Arabia has the potential to become a dominant force in regional HPV diagnostics market.

Human Papilloma Virus Testing Market Segmentation

Application

• Cervical Cancer Screening
• Vaginal Cancer Screening

Product

• Consumables
• Instruments
• Services

Technology

• Polymerase chain reaction (PCR)
• Liquid-based cytology
• Immunodiagnostics
• Hybrid Capture
• Others

End Use

• Hospitals & Clinics
• Laboratories
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa

All companies have been covered

• Overview
• Key Persons
• Recent Development & Strategies
• Financial Insights

Company Analysis

• Abbott Laboratories
• BioMerieux SA
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• Siemens Healthineers AG
• Hologic Inc
• Qiagen NV
• F. Hoffmann-La Roche Ltd

Table of Contents

1. Introduction

2. Research Methodology

• 2.1 Data Source
  • 2.1.1 Primary Sources
  • 2.1.2 Secondary Sources
• 2.2 Research Approach
  • 2.2.1 Top-Down Approach
  • 2.2.2 Bottom-Up Approach
• 2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Human Papilloma Virus Testing Market

• 5.1 Historical Market Trends
• 5.2 Market Forecast

6. Human Papilloma Virus Testing Market Share Analysis

• 6.1 By Application
• 6.2 By Product
• 6.3 By Technology
• 6.4 By End Use
• 6.5 By Countries

7. Application

• 7.1 Cervical Cancer Screening
• 7.2 Vaginal Cancer Screening

8. Product

• 8.1 Consumables
• 8.2 Instruments
• 8.3 Services

9. Technology

• 9.1 Polymerase chain reaction (PCR)
• 9.2 Liquid-based cytology
• 9.3 Immunodiagnostics
• 9.4 Hybrid Capture
• 9.5 Others

10. End Use

• 10.1 Hospitals & Clinics
• 10.2 Laboratories
• 10.3 Others

11. Countries

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
• 11.2 Europe
  • 11.2.1 France
  • 11.2.2 Germany
  • 11.2.3 Italy
  • 11.2.4 Spain
  • 11.2.5 United Kingdom
  • 11.2.6 Belgium
  • 11.2.7 Netherlands
  • 11.2.8 Turkey
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Thailand
  • 11.3.6 Malaysia
  • 11.3.7 Indonesia
  • 11.3.8 Australia
  • 11.3.9 New Zealand
• 11.4 Latin America
  • 11.4.1 Brazil
  • 11.4.2 Mexico
  • 11.4.3 Argentina
• 11.5 Middle East & Africa
  • 11.5.1 Saudi Arabia
  • 11.5.2 UAE
  • 11.5.3 South Africa

12. Porter's Five Forces Analysis

• 12.1 Bargaining Power of Buyers
• 12.2 Bargaining Power of Suppliers
• 12.3 Degree of Rivalry
• 12.4 Threat of New Entrants
• 12.5 Threat of Substitutes

13. SWOT Analysis

• 13.1 Strength
• 13.2 Weakness
• 13.3 Opportunity
• 13.4 Threat

14. Key Players Analysis

• 14.1 Abbott Laboratories
  • 14.1.1 Overview
  • 14.1.2 Key Persons
  • 14.1.3 Recent Development & Strategies
  • 14.1.4 Revenue Analysis
• 14.2 BioMerieux SA
  • 14.2.1 Overview
  • 14.2.2 Key Persons
  • 14.2.3 Recent Development & Strategies
  • 14.2.4 Revenue Analysis
• 14.3 Bio-Rad Laboratories, Inc.
  • 14.3.1 Overview
  • 14.3.2 Key Persons
  • 14.3.3 Recent Development & Strategies
  • 14.3.4 Revenue Analysis
• 14.4 Epigenomics AG
  • 14.4.1 Overview
  • 14.4.2 Key Persons
  • 14.4.3 Recent Development & Strategies
  • 14.4.4 Revenue Analysis
• 14.5 Siemens Healthineers AG
  • 14.5.1 Overview
  • 14.5.2 Key Persons
  • 14.5.3 Recent Development & Strategies
  • 14.5.4 Revenue Analysis
• 14.6 Hologic Inc
  • 14.6.1 Overview
  • 14.6.2 Key Persons
  • 14.6.3 Recent Development & Strategies
  • 14.6.4 Revenue Analysis
• 14.7 Qiagen NV
  • 14.7.1 Overview
  • 14.7.2 Key Persons
  • 14.7.3 Recent Development & Strategies
  • 14.7.4 Revenue Analysis
• 14.8 F. Hoffmann-La Roche Ltd
  • 14.8.1 Overview
  • 14.8.2 Key Persons
  • 14.8.3 Recent Development & Strategies
  • 14.8.4 Revenue Analysis